- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02454387
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacology of ONO-4474 in Healthy Volunteers
June 29, 2016 updated by: Ono Pharmaceutical Co. Ltd
A Double-blind, Single and Multiple Ascending Dose, Randomised, Placebo-controlled Study, in Healthy Adult and Elderly Subjects Exploring Safety, Tolerability, Pharmacokinetics of ONO-4474 and Pharmacology of ONO-4474 in NGF-hyperalgesia
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacology of ONO-4474 in healthy volunteers.
Study Overview
Status
Completed
Conditions
Detailed Description
A Double-blind, Multi-centre, Single Dose, Single and Multiple Ascending Dose, Four-part, Randomised, Placebo-controlled Study in Healthy Adult and Elderly Subjects Exploring the Safety, Tolerability, Pharmacokinetics of ONO-4474 in Fed and Fasted Conditions, and Pharmacology of ONO-4474 in NGF-hyperalgesia.
Study Type
Interventional
Enrollment (Actual)
141
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aalborg, Denmark
- Aalborg Clinical Site
-
-
-
-
-
Nottingham, United Kingdom
- Nottingham Clinical SIte
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male subjects aged 18-55 years inclusive (Parts A and C); healthy male and female subjects aged 18-55 years inclusive (Part B); healthy male and female subjects aged 65 and over (Part D)
- Subjects with a body mass index of 18.0-30.0 kg/m2 inclusive
Exclusion Criteria:
- Subjects who have a clinically relevant history or presence of any clinically significant disease or disorder
- Current smokers or those that have smoked or used nicotine products within 6 months of the Screening visit
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: ONO-4474 Part A1
Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
|
Healthy volunteers
Other Names:
|
Placebo Comparator: Experimental: ONO-4474 Placebo Part A1
Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
|
Healthy volunteers
Other Names:
|
Experimental: Experimental: ONO-4474 Part A2
Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo
|
Healthy volunteers
Other Names:
|
Placebo Comparator: Experimental: ONO-4474 Placebo Part A2
Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo
|
Healthy volunteers
Other Names:
|
Experimental: Experimental: ONO-4474 Part B
Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
|
Healthy volunteers
Other Names:
|
Placebo Comparator: Experimental: ONO-4474 Placebo Part B
Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
|
Healthy volunteers
Other Names:
|
Experimental: Experimental: ONO-4474 Part C
NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design
|
Healthy volunteers
Other Names:
|
Placebo Comparator: Experimental: ONO-4474 Placebo Part C
NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design
|
Healthy volunteers
Other Names:
|
Experimental: Experimental: ONO-4474 Part D
Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
|
Healthy volunteers
Other Names:
|
Placebo Comparator: Experimental: ONO-4474 Placebo Part D
Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
|
Healthy volunteers
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and tolerability of ONO-4474 across ascending single and multiple doses using number of adverse events
Time Frame: Up to Day 28
|
Up to Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum plasma concentration of ONO-4474 (Cmax)
Time Frame: Day 1 and at Day 7
|
Day 1 and at Day 7
|
|
ONO-4474 Plasma Area Under the Curve from Time Zero to 24 hour after dosing (AUC24)
Time Frame: Day 1 and at Day 7
|
Day 1 and at Day 7
|
|
Time to Reach Maximum Observed Plasma concentration (Tmax) of ONO-4474
Time Frame: Day 1 and at Day 7
|
Day 1 and at Day 7
|
|
Plasma Decay half life (T1/2) of ONO-4474
Time Frame: Day 1 and at Day 7
|
Day 1 and at Day 7
|
|
Part C only - Evaluation of ONO-4474 vs. placebo on walking soreness using a Likert scale
Time Frame: 3hr and 24hr after NGF injection
|
3hr and 24hr after NGF injection
|
|
Part C only: Assessment of pharmacology of ONO-4474 using change in pressure pain threshold after NGF injection.
Time Frame: 3hr and 24hr after NGF injection
|
Pressure algometry at site of NGF injection (anterior tibialis)
|
3hr and 24hr after NGF injection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Drug Development Division, Ono Pharmaceutical Co. Ltd
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2015
Primary Completion (Actual)
April 1, 2016
Study Completion (Actual)
April 1, 2016
Study Registration Dates
First Submitted
April 29, 2015
First Submitted That Met QC Criteria
May 22, 2015
First Posted (Estimate)
May 27, 2015
Study Record Updates
Last Update Posted (Estimate)
June 30, 2016
Last Update Submitted That Met QC Criteria
June 29, 2016
Last Verified
January 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ONO-4474-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
University of VermontCompletedOsteoarthritis of Knee | Osteoarthritis Of HipUnited States
-
Hospital for Special Surgery, New YorkRoyal Infirmary of EdinburghRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited States, United Kingdom
-
Ottawa Hospital Research InstituteNot yet recruitingKnee Osteoarthritis | Hip Osteoarthritis
-
University Hospital, LilleCompleted
-
Massachusetts General HospitalNewton-Wellesley Hospital; The New England Baptist HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
Clinical Trials on ONO-4474 Part A1
-
Ono Pharmaceutical Co. LtdTerminatedPain | Osteoarthritis, KneePoland, Hungary, Spain, Denmark, United Kingdom
-
University of PittsburghCompletedDepression | Stress | Inflammatory Bowel Diseases | Dietary Habits | Mental Health Wellness 1 | Happiness | Consciousness, Level Altered | EcstasyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingClassic Hodgkin Lymphoma | Lymphocyte-Rich Classic Hodgkin Lymphoma | Ann Arbor Stage IB Hodgkin Lymphoma | Ann Arbor Stage II Hodgkin Lymphoma | Ann Arbor Stage IIA Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma | Ann Arbor Stage I Hodgkin Lymphoma | Ann Arbor Stage I Mixed Cellularity... and other conditionsUnited States